Scott M. Herbig
23Patents
14h-index
27Co-inventors
81Inventor score
Filing activity: Nov 30, 1990 → Mar 13, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6706283B1 | Controlled release by extrusion of solid amorphous dispersions of drugs | Human Necessities | 116 | Expired |
| US5698220A | Asymmetric membranes in delivery devices | Human Necessities | 97 | Expired |
| US5612059A | Use of asymmetric membranes in delivery devices | Human Necessities | 89 | Expired |
| US6984403B2 | Azithromycin dosage forms with reduced side effects | Human Necessities | 60 | Expired |
| US5798119A | Osmotic-delivery devices having vapor-permeable coatings | Performing Operations; Transporting | 55 | Expired |
| US5603953A | Supported liquid membrane delivery devices | Human Necessities | 34 | Expired |
| US6517866B1 | Sertraline salts and sustained-release dosage forms of sertraline | Human Necessities | 32 | Expired |
| US5827538A | Osmotic devices having vapor-permeable coatings | Physics | 30 | Expired |
| US8257741B2 | Solid pharmaceutical dispersions with enhanced bioavailability | Performing Operations; Transporting | 25 | Expired |
| US8263128B2 | Solid pharmaceutical dispersions with enhanced bioavailability | Performing Operations; Transporting | 22 | Expired |
| US5609590A | PH-triggered osmotic bursting delivery devices | Human Necessities | 21 | Expired |
| US7550158B2 | Controlled release by extrusion of solid amorphous dispersions of drugs | Human Necessities | 17 | Expired |
| US5876752A | Use of interfacially-polymerized membranes in delivery devices | Human Necessities | 15 | Expired |
| US5358502A | PH-triggered osmotic bursting delivery devices | Human Necessities | 14 | Expired |
| US5091080A | Adsorbents for the removal of volatile substances from aqueous systems | Chemistry; Metallurgy | 13 | Expired |
| US6641840B2 | Sustained release formulations for growth hormone secretagogues | Human Necessities | 13 | Expired |
| US8367118B2 | Solid pharmaceutical dispersions with enhanced bioavailability | Performing Operations; Transporting | 9 | Active |
| US8431159B2 | Solid pharmaceutical dispersions with enhanced bioavailability | Performing Operations; Transporting | 8 | Active |
| US8337899B2 | Solid pharmaceutical dispersions with enhanced bioavailability | Performing Operations; Transporting | 8 | Active |
| US7887844B2 | Multiparticulate crystalline drug compositions having controlled release profiles | Human Necessities | 6 | Active |
| US9937181B2 | Tofacitinib oral sustained release dosage forms | Human Necessities | 3 | Active |
| US10639309B2 | Tofacitinib oral sustained release dosage forms | Human Necessities | 2 | Active |
| US11253523B2 | Tofacitinib oral sustained release dosage forms | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.